Table 2.
Correlation of PD-L1 combined positive score (CPS) with tumor mutation burden (TMB) according to primary tumor.
| PD-L1 CPS * | Total (n = 413) | Gastric Cancer (n = 126) | Biliary Tract Cancer (n = 73) | |||||||||
| Negative (n = 105) |
Low (n = 265) |
High (n = 43) |
p-value | Negative (n = 41) |
Low (n = 82) |
High (n=2) |
p-value | Negative (n = 15) |
Low (n = 44) |
High (n = 14) |
p-value | |
| TMB < 10 | 100 (95.2%) | 230 (86.8%) | 33 (76.6%) |
0.005 | 40 (97.6%) | 73 (89.0%) | 1 (33.3%) |
0.001 | 14 (93.3%) | 37 (84.1%) | 8 (57.1%) |
0.032 |
| TMB ≥ 10 | 5 (4.8%) |
35 (13.2%) |
10 (23.3%) |
1 (2.4%) |
9 (11.0%) |
2 (66.7%) |
1 (6.7%) |
7 (15.9%) |
6 (42.9%) |
|||
| PD-L1 CPS ** | Total (n = 413) | Gastric Cancer (n = 126) | Biliary Tract Cancer (n = 73) | |||||||||
| Negative (n = 107) |
Positive (n = 306) |
p-value | Negative (n = 41) |
Positive (n = 85) |
p-value | Negative (n = 16) | Positive (n = 57) | p-value | ||||
| TMB < 10 | 101 (94.4%) |
262 (85.6%) |
0.017 | 40 (97.6%) |
74 (87.1%) |
0.060 | 15 (93.8%) |
44 (77.2%) |
0.137 | |||
| TMB ≥ 10 | 6 (5.6%) |
44 (14.4%) |
1 (2.4%) |
11 (12.9%) |
1 (6.2%) |
13 (22.8%) |
||||||
* Negative: PD-L1 expression < 1, Low: 1 ≤ PD-L1 expression < 50, High: 50 ≤ PD-L1 expression ** Negative: PD-L1 expression < 1, Positive: 1 ≤ PD-L1 expression.